CABANA post-publication takeaways for catheter ablation of atrial fibrillation April 03, 2019 Overview Show transcript Overview Mayo Clinic electrophysiologists Douglas L. Packer, M.D., Thomas M. Munger, M.D., and Peter A. Noseworthy, M.D., discuss the outcomes, strengths and limitations of the Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial. CABANA, which enrolled 2,200 patients, was one of the largest and most highly anticipated ablation trials ever completed. The goal was to compare drug therapy with catheter ablation in patients with atrial fibrillation to determine the best treatment approach. CABANA showed that ablation is significantly better than drug therapy for preventing the recurrence of atrial fibrillation. This video first appeared on theheart.org | Medscape Cardiology. Share Doximity Facebook LinkedIn Twitter Print details Email Receive Mayo Clinic news in your inbox. Sign up Related ContentArticleMayo Clinic study shows AI could enable accurate, inexpensive screening for atrial fibrillationArticleCABANA trial results announced at Heart Rhythm Society scientific sessions: The neutral trial that wasn't neutralArticleDiscoverys Edge Getting to the heart of sleep VID-20460201 Home CABANA Post-Publication Takeaways for Catheter Ablation of AF